These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 29234249)

  • 1. Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response.
    Guarducci C; Bonechi M; Boccalini G; Benelli M; Risi E; Di Leo A; Malorni L; Migliaccio I
    Breast Care (Basel); 2017 Oct; 12(5):304-308. PubMed ID: 29234249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer-A Review of the Literature.
    Stanciu IM; Parosanu AI; Orlov-Slavu C; Iaciu IC; Popa AM; Olaru CM; Pirlog CF; Vrabie RC; Nitipir C
    Diagnostics (Basel); 2023 Mar; 13(5):. PubMed ID: 36900131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
    Shah AN; Cristofanilli M
    Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel.
    Trapé AP; Liu S; Cortes AC; Ueno NT; Gonzalez-Angulo AM
    J Cancer; 2016; 7(8):947-56. PubMed ID: 27313785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A narrative review about CDK4/6 inhibitors in the setting of drug resistance: updates on biomarkers and therapeutic strategies in breast cancer.
    Zhao S; Zhang H; Yang N; Yang J
    Transl Cancer Res; 2023 Jun; 12(6):1617-1634. PubMed ID: 37434680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials.
    Messina C; Cattrini C; Buzzatti G; Cerbone L; Zanardi E; Messina M; Boccardo F
    Breast Cancer Res Treat; 2018 Nov; 172(1):9-21. PubMed ID: 30054831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
    Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
    Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer.
    Wu Y; Zhang Y; Pi H; Sheng Y
    Cancer Manag Res; 2020; 12():3477-3487. PubMed ID: 32523378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting CDK4/6 pathways and beyond in breast cancer.
    Ribnikar D; Volovat SR; Cardoso F
    Breast; 2019 Feb; 43():8-17. PubMed ID: 30359883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer.
    Migliaccio I; Leo A; Galardi F; Guarducci C; Fusco GM; Benelli M; Di Leo A; Biganzoli L; Malorni L
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34072070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of CDK4/6 Inhibitors in Breast Cancer.
    Murphy CG
    Curr Treat Options Oncol; 2019 May; 20(6):52. PubMed ID: 31101994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach.
    Gul A; Leyland-Jones B; Dey N; De P
    Am J Cancer Res; 2018; 8(12):2359-2376. PubMed ID: 30662797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.
    O'Sullivan CC
    Expert Opin Pharmacother; 2016 Aug; 17(12):1657-67. PubMed ID: 27322766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story.
    Cogliati V; Capici S; Pepe FF; di Mauro P; Riva F; Cicchiello F; Maggioni C; Cordani N; Cerrito MG; Cazzaniga ME
    Life (Basel); 2022 Mar; 12(3):. PubMed ID: 35330128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK4-6 inhibitors in breast cancer: current status and future development.
    Choo JR; Lee SC
    Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1123-1138. PubMed ID: 30360668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Resistance Mechanisms and Clinical Implications in Patients with KRAS Mutated-Metastatic Breast Cancer and Resistance to CDK4/6 Inhibitors.
    Raimondi L; Raimondi FM; Pietranera M; Di Rocco A; Di Benedetto L; Miele E; Lazzeroni R; Cimino G; Spinelli GP
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33923563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
    van Ommen-Nijhof A; Konings IR; van Zeijl CJJ; Uyl-de Groot CA; van der Noort V; Jager A; Sonke GS;
    BMC Cancer; 2018 Nov; 18(1):1146. PubMed ID: 30458732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting CDK4/6 in patients with cancer.
    Hamilton E; Infante JR
    Cancer Treat Rev; 2016 Apr; 45():129-38. PubMed ID: 27017286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.